Results 1 to 10 of about 4,505 (178)

A systematic review and meta-analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D). [PDF]

Diabet Med
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Kelly M, Saluja S, Ellis HL, Jamil S, Whyte MB, Heald A.   +5 more
europepmc   +2 more sources

Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events [PDF]

BMC Medical Genomics
Background Saxagliptin is a DPP-4 inhibitor widely used to manage type 2 diabetes, though genetic contributors to variability in response remain unclear. This study aimed to identify genetic variants associated with the efficacy and safety of saxagliptin
Marc-Olivier Pilon, Simon de Denus, Géraldine Asselin, Marc-André Legault, Hervira Brenda Ngongang Kwandjang, Amina Barhdadi, Louis-Philippe Lemieux Perreault, Diane Valois, Ian Mongrain, Carolina Haefliger, Dirk S. Paul, Ewan R. Pearson, Jean-Claude Tardif, Marie-Pierre Dubé   +13 more
doaj   +2 more sources

Heterogeneous effect of saxagliptin on glucose fluctuation and β-cell function in T1DM: a multicentre, randomised trial [PDF]

Nutrition & Diabetes
Background and Aims We aimed to explore whether saxagliptin, a dipeptidyl peptidase-IV inhibitor, could ameliorate glucose fluctuations and maintain β-cell function in T1DM.
Yun Shi, Min Shen, Yong Gu, Yang Chen, Kuanfeng Xu, Ji Hu, Chen Fang, Heming Guo, Ning Xu, Guofeng Wang, Weiping Lu, Sha Tao, Songqing Zhao, Chengxia Fang, Jianhua Ma, Rengna Yan, Rui Sun, Li Qian, Chenguang Wu, Hui Jiang, Tao Yang   +20 more
doaj   +2 more sources

Pharmacokinetic interaction of saxagliptin with andrographolide and their hypoglycemic effect in type 2 diabetes rats [PDF]

Acta Poloniae Pharmaceutica, 2023
Controlling blood glucose is the primary therapeutic strategy for T2DM. Both saxagliptin and andrographolide possess hypoglycemic effects, which makes the combination easy.
Suyan Wu, Haifei Pan, Yingying Huang
doaj   +1 more source

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy

Frontiers in Pharmacology, 2021
We aimed to develop a physiological-based pharmacokinetic and dipepidyl peptidase 4 (DPP-4) occupancy model (PBPK-DO) characterized by two simultaneous simulations to predict pharmacokinetic (PK) and pharmacodynamic changes of saxagliptin and metabolite ...
Gang Li, Bowen Yi, Jingtong Liu, Xiaoquan Jiang, Fulu Pan, Wenning Yang, Haibo Liu, Yang Liu, Guopeng Wang   +8 more
doaj   +1 more source

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

Frontiers in Physiology, 2018
Some oral anti-hyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 (DPP4), have been linked to the increased risk of heart failure (HF) in type-2 diabetic patients.
Chintan N. Koyani, Christopher Trummer, Niroj Shrestha, Susanne Scheruebel, Benjamin Bourgeois, Ioanna Plastira, Sandra Kickmaier, Harald Sourij, Harald Sourij, Peter P. Rainer, Tobias Madl, Tobias Madl, Wolfgang Sattler, Brigitte Pelzmann, Ernst Malle, Dirk von Lewinski   +15 more
doaj   +1 more source

Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial

Signal Transduction and Targeted Therapy, 2023
Disease modifying therapies aiming to preserve β-cell function in patients with adult-onset autoimmune type 1 diabetes are lacking. Here, we conducted a multi-centre, randomized, controlled trial to assess the β-cell preservation effects of saxagliptin ...
Xiang Yan, Xia Li, Bingwen Liu, Jiaqi Huang, Yufei Xiang, Yuhang Hu, Xiaohan Tang, Ziwei Zhang, Gan Huang, Zhiguo Xie, Houde Zhou, Zhenqi Liu, Xiangbing Wang, Richard David Leslie, Zhiguang Zhou   +14 more
doaj   +1 more source

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Diabetology & Metabolic Syndrome, 2012
Background The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.
Frederich Robert, McNeill Robert, Berglind Niklas, Fleming Douglas, Chen Roland   +4 more
doaj   +1 more source

The protective effects of saxagliptin against lipopolysaccharide (LPS)-induced inflammation and damage in human dental pulp cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Bacteria play a pivotal role in the pathological initiation and progression of pulpitis. Lipopolysaccharide (LPS) is recognized as a major component of the outer wall of Gram-negative bacteria.
Xinxing Guo, Jing Chen
doaj   +1 more source

Enhanced Diabetic Wound Healing Using Electrospun Biocompatible PLGA-Based Saxagliptin Fibrous Membranes

Nanomaterials, 2022
Delayed diabetic wound healing is an adverse event that frequently leads to limb disability or loss. A novel and promising vehicle for the treatment of diabetic wounds is required for clinical purposes.
Chen-Hung Lee, Shu-Chun Huang, Kuo-Chun Hung, Chia-Jung Cho, Shih-Jung Liu   +4 more
doaj   +1 more source